↓ Skip to main content

Circulating protein and antibody biomarker for personalized cancer immunotherapy

Overview of attention for article published in Journal for Immunotherapy of Cancer, August 2016
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
34 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Circulating protein and antibody biomarker for personalized cancer immunotherapy
Published in
Journal for Immunotherapy of Cancer, August 2016
DOI 10.1186/s40425-016-0150-0
Pubmed ID
Authors

Jianda Yuan

Abstract

Immune checkpoint blockade therapies are revolutionizing standard cancer treatments. Immune checkpoint inhibitors likely function to enhance the tumor specific antigen response in order to achieve favorable clinical outcomes. Thus, continuous efforts to identify the common tumor-specific antigens are essential for the broad clinical application of these therapies. Several immunoproteomics approaches have been used in order to screen for this specificity. In a recent article from Jhaveri and colleagues published in the February issue of Cancer Immunology Research, antibody biomarkers were screened in pancreatic cancer patients who received allogeneic, granulocyte-macrophage colony stimulating factor-secreting pancreatic cancer vaccine (GVAX) by using a serum antibody-based SILAC immunoprecipitation (SASI) approach. Using this assay, several new tumor antigens (MYPT1, PSMC5 and TRFR) were identified that were found to have significantly different expression in tumors compared with normal tissue. Moreover, patients with detectable antibodies showed improved disease-free survival after GVAX therapy. These targets need to be further validated to determine the full spectrum of tumor antigen immunogencity and their potential clinical application. In addition to antibodies, circulating protein, DNA and RNA in peripheral blood are under clinical investigation as liquid biopsies and have the potential to provide guidance for future personalized cancer immunotherapy.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 3%
Unknown 33 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 7 21%
Researcher 6 18%
Student > Master 5 15%
Student > Bachelor 4 12%
Other 3 9%
Other 6 18%
Unknown 3 9%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 10 29%
Agricultural and Biological Sciences 7 21%
Medicine and Dentistry 5 15%
Pharmacology, Toxicology and Pharmaceutical Science 2 6%
Unspecified 1 3%
Other 5 15%
Unknown 4 12%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 August 2016.
All research outputs
#7,437,269
of 8,604,226 outputs
Outputs from Journal for Immunotherapy of Cancer
#329
of 342 outputs
Outputs of similar age
#214,001
of 256,975 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#11
of 11 outputs
Altmetric has tracked 8,604,226 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 342 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 256,975 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.